



**DEPARTMENT OF PHARMACOLOGY**

**NEW DRUG UPDATE**

*Series No: 71, MAY, 2025*

S.NO	DRUG & APPROVAL DATE	MECHANISM	INDICATION	DOSAGE FORMS
1.	Avutometinib & Defactinib (08.05.2025)	Kinase inhibitor- reduces cell proliferation	Low Grade serous Ovarian Carcinoma	Capsules/ Tablets
2.	Telisotuzumab vedotin- tllv (14. 05.2025)	Antibody-Drug Conjugate: targets MET gene specific marker & Release MMAE (monomethyl auristatin E) → destroys cancer cells.	Non Small Cell Lung Cancer	Lyophilized Powder for Intravenous injection
3.	COVID-19 Vaccine, Adjuvant (16.05.2025)	Protein-based, non-mRNA Vaccine for active Immunization to prevent COVID-19 caused by (SARS-CoV-2).	Severe Acute Respiratory Syndrome Coronavirus-2	Intramuscular Injectable Suspension
4.	Ustekinumab-hmny (22.05.2025)	Human Monoclonal Antibody (Interleukin) IL 12 & 23 antagonist	Plaque Psoriasis, Psoriatic arthritis, Crohn's disease & Ulcerative colitis	Pre-filled S.C & Vials -I.V Injection
5.	Treprostinil (23.05.2025)	Prostacyclin analog- direct vasodilator of both Pulmonary & Systemic vascular beds→ reduces Pulmonary Artery Pressure & Improves Systemic oxygenation	Pulmonary Arterial Hypertension & Pulmonary hypertension associated with Interstitial Lung Disease.	Inhaled dry powder
6.	Acoltremon (28.05.2025)	TRPM8 thermoreceptor agonist-(neuromodulator) stimulates corneal sensory nerves - Increase natural tear production	Dry eye disease	Ophthalmic solution

**Contact Details:**

Email your suggestions to : [hodpharmacology@kmchihsr.edu.in](mailto:hodpharmacology@kmchihsr.edu.in)

Website : <http://www.kmchihsr.edu.in>